8 minutes

According to Tolstoy, patience and time are the most powerful warriors. When it comes to the pandemic, they certainly seem to have been important allies. The time for vaccines has finally arrived. However, we have also been told to not let our guard down. Vaccines are not the only secure gateway, and encompassing a healthy lifestyle is still needed for effective herd immunity and to protect ourselves and our loved ones. While it seems logical, is there science to back up which people are considered vulnerable, even if vaccinated? What other science can we turn to, for protection, in addition to the vaccine?

Several factors influence our response to vaccinations. Of course, the response varies depending on the specific vaccine to be delivered. In general, any factor associated with a weaker immune response is more likely to result in worse outcomes following vaccinations. The opposite is also mostly true. The literature shows that the use of immunostimulants as adjuncts to vaccines tends to improve outcomes.

Of all factors, age seems to have the greatest impact on vaccines. Neonates have an immature immune system and rely on maternal antibodies. Preexisting maternal antibodies inhibits the infant’s antibody responses after vaccinations. Neonates and young infants are less likely to develop an appropriate initial antibody response but are also more likely to see those antibodies wane prematurely. The effect of age at inoculation has been examined extensively with the measles vaccine. A meta-analysis of 20 studies showed that the proportion of infants seroconverting (producing detectable antibodies against the disease) after one dose of measles vaccination increases from 50% at 4 months of age to 85% at 8 months.

It is also well-established that seniors are more vulnerable to infections partly due to a weakened immune response. Seniors also tend to produce a weaker reaction after vaccinations, and antibody levels are more likely to decrease prematurely post inoculation. ,  ,  ,  ,  Genetics also play an important role, with studies showing that different ethnic groups living in similar circumstances have different responses to vaccinations and see different declines in antibodies. ,  ,  Given that these variations are caused by gene polymorphisms and differences in components of the immune response, their effects are variable and difficult to predict.

The comorbidities can have a significant impact on our immune response. For instance, if you suffer from an active infection when getting a vaccine, especially if you are feverish at the time of the inoculation, you are less likely to have a favourable immune response. ,  ,  Patients with autoimmune disorders, such as celiac disease or diabetes mellitus, have also been shown to produce antibodies following fewer vaccinations. Patients requiring dialysis for chronic kidney failure have less favourable responses to immunizations due to factors such as uraemia, malnutrition, and a general state of immunosuppression.

Poor nutritional status is known to negatively affect the immune system. Several abnormalities in immune function have been linked with malnutrition, including deficits in secretory IgA, complement production, gut-barrier function, and T‑cell memory maintenance. Malnutrition reduces the effectiveness of the oral polio vaccine and perhaps others.

Skin Surface

What Can Help?

Exercise exerts a positive effect on the immune system. A study looking at the effects of exercise on the response to influenza vaccinations in adults over the age of 62 showed that exercising for at least 20 minutes three times per week increases the antibody response postvaccination.

The microflora in the intestinal tract is an important regulator of the immune system. Studies show that the microflora influences our reaction to vaccinations. A systematic review looked at 26 studies, comprising 3,812 participants, using 40 different probiotic strains with 17 different vaccines. The results showed that probiotics were effective at improving outcomes postvaccination in about half of the studies. Probiotics were particularly effective when combined with oral vaccines. Positive effects were seen with diphtheria, hepatitis A  and B, polio, and rotavirus and influenza  ,  vaccinations.

The literature also shows that immune-stimulating supplements improve outcomes after vaccinations. In animal studies, supplementation with echinacea pre‑ and postvaccination significantly augments the immune response and the production of influenza antibodies. Another study showed that simply adding thyme to the feed of chickens improves their immune response following vaccination against influenza. Animal studies show similar findings with astragalus enhancing the response to an avian infectious bronchitis virus vaccine. Lactoferrin is another supplement with demonstrated immune-stimulating effects. In animal studies, the combination of lactoferrin with immunization against influenza increased the production of antibodies. Studies in mice feed polysaccharides from medicinal mushrooms, ginger, and tangerine peel for 30 days following influenza vaccination had an improved immune response, and the mice were less likely to develop inflammation in the lungs.

Most importantly, human studies in institutionalized elderly patients show that receiving low-dose supplements of zinc and selenium significantly increased the immune response after vaccination, thereby improving the effectiveness of the vaccines.

Conclusion

The lessons are clear: Those with a reduced ability to mount an immune response are more likely to have a poor response following inoculations. Unfortunately, this also means that those most likely to need the protection from vaccines are the ones less likely to obtain it. Healthier lifestyles as well as immunostimulants have potential to be powerful helpers when it comes to improving outcomes following vaccines.


Références
  1. Voysey, M., D.F. Kelly, T.R. Fanshawe, M. Sadarangani, K.L. O’Brien, R. Perera, and A.J. Pollard. “The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: An individual participant meta-analysis.” JAMA Pediatrics, Vol. 171, No. 7 (2017): 637–646.
  2. Halsey, N., and A. Galazka. “The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.” Bulletin of the World Health Organization, Vol. 63, No. 6 (1985): 1151–1169.
  3. Lochlainn, L.N., B. de Gier, N. van der Maas, N. Rots, R. van Binnendijk, H. de Melker, and S. Hahné. Measles vaccination below 9 months of age: Systematic literature review and meta‐analyses of effects and safety (draft 3). Bilthoven: National Institute for Public Health and the Environment, 2015.
  4. Gardner, I.D. “The effect of aging on susceptibility to infection.” Reviews of Infectious Disease, Vol. 2, No. 5 (1980): 801–810.
  5. D’Acremont, V., C. Herzog, and B. Genton. “Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.” Journal of Travel Medicine, Vol. 13, No. 2 (2006): 78–83.
  6. Bernstein, E.D., E.M. Gardner, E. Abrutyn, P. Gross, and D.M. Murasko. “Cytokine production after influenza vaccination in a healthy elderly population.” Vaccine, Vol. 16, No. 18 (1998): 1722–1731.
  7. McElhaney, J.E., G.S. Meneilly, B.L. Beattie, C.D. Helgason, S.F. Lee, R.D. Devine, and R.C. Bleackley. “The effect of influenza vaccination on IL2 production in healthy elderly: Implications for current vaccination practices.” Journal of Gerontology, Vol. 47, No. 1 (1992): M3–M8.
  8. Bayas, J.M., A. Vilella, M.J. Bertran, J. Vidal, J. Batalla, M.A. Asenjo, and L.L. Salleras. “Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary?” Epidemiology and Infection, Vol. 127, No. 3 (2001): 451–460.
  9. Kao, T.M., S.M. Hsieh, H.C. Kung, Y.C. Lee, K.C. Huang, L.M. Huang, F.Y. Chang, et al. “Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.” Vaccine, Vol. 28, No. 38 (2010): 6159–6163.
  10. Wang, L.‑Y., C.‑T. Hu, T.‑Y. Ho, and H.H. Lin. “Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area.” Vaccine, Vol. 24, No. 20 (2006): 4427–4432.
  11. Asturias, E.J., C. Mayorga, C. Caffaro, P. Ramirez, M. Ram, T. Verstraeten, R. Clemens, and N.A. Halsey. “Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status.” Vaccine, Vol. 27, No. 27 (2009): 3650–3654.
  12. Alper, C.A., M.S. Kruskall, D. Marcus‑Bagley, D.E. Craven, A.J. Katz, S.J. Brink, J.L. Dienstag, Z. Awdeh, and E.J. Yunis. “Genetic prediction of nonresponse to hepatitis B vaccine.” New England Journal of Medicine, Vol. 321, No. 11 (1989): 708–712.
  13. Davila, S., F.E.M. Froeling, A. Tan, C. Bonnard, G.J. Boland, H. Snippe, M.L. Hibberd, and M. Seielstad. “New genetic associations detected in a host response study to hepatitis B vaccine.” Genes and Immunity, Vol. 11, No. 3 (2010): 232–238.
  14. Dennehy, P.H., C.L. Saracen, and G. Peter. “Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.” Pediatrics, Vol. 94, No. 4, Pt. 1 (1994): 514–516.
  15. Krober, M.S., C.E. Stracener, and J.W. Bass. “Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.” JAMA, Vol. 265, No. 16 (1991): 2095–2096.
  16. Usen, S., P. Milligan, C. Ethevenaux, B. Greenwood, and K. Mulholland. “Effect of fever on the serum antibody response of Gambian children to Haemophilus influenzae type b conjugate vaccine.” The Pediatric Infectious Disease Journal, Vol. 19, No. 5 (2000): 444–449.
  17. Miles, D.J.C., M. Sanneh, B. Holder, S. Crozier, S. Nuyamweya, E.S. Touray, M.S. Palmero, et al. “Cytomegalovirus infection induces T‑cell differentiation without impairing antigen-specific responses in Gambian infants.” Immunology, Vol. 124, No. 3 (2008): 388–400.
  18. Chow, K.M., M.C. Law, C.B. Leung, C.C. Szeto, and P. Kam‑Tao Li. “Antibody response to hepatitis B vaccine in end-stage renal disease patients.” Nephron. Clinical Practice, Vol. 103, No. 3 (2006): c89–c93.
  19. Calder, P.C., A.C. Carr, A.F. Gombart, and M. Eggersdorfer. “Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections.” Nutrients, Vol. 12, No. 4 (2020): 1181.
  20. Rytter, M.J.H., L. Kolte, A. Briend, H. Friis, and V.B. Christensen. “The immune system in children with malnutrition—A systematic review.” PLoS One, Vol. 9, No. 8 (2014): e105017.
  21. Haque, R., C. Snider, Y. Liu, J.Z. Ma, L. Liu, U. Nayak, J.C. Mychaleckyj, et al. “Oral polio vaccine response in breast fed infants with malnutrition and diarrhea.” Vaccine, Vol. 32, No. 4 (2014): 478–482.
  22. Campbell, J.P., and J.E. Turner. “Debunking the myth of exercise-induced immune suppression: redefining the impact of exercise on immunological health across the lifespan. Frontiers in Immunology, Vol. 9 (2018): 648.
  23. Kohut, M.L., M.M. Cooper, M.S. Nickolaus, D.R. Russell, and J.E. Cunnick. “Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals.” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, Vol. 57, No. 9 (2002): M557–M562.
  24. Zhang, C.‑X., H.‑Y. Wang, and T.‑X. Chen. “Interactions between intestinal microflora/probiotics and the immune system.” BioMed Reesearch International, Vol. 2019 (2019): 6764919.
  25. Zimmermann, P., and N. Curtis. “The influence of the intestinal microbiome on vaccine responses.” Vaccine, Vol. 36, No. 30 (2018): 4433–4439.
  26. Zimmermann, P., and N. Curtis. “The influence of probiotics on vaccine responses—A systematic review.” Vaccine, Vol. 36, No. 2 (2018): 207–213.
  27. West, C.E., L. Gothefors, M. Granström, H. Käyhty, M.L. Hammarström, and O. Hernell. “Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines.” Pediatric Allergy and Immunology, Vol. 19, No. 1 (2007): 53–60.
  28. Redondo, N., E. Nova, A. Gheorghe, L.E. Díaz, A. Hernández, and A. Marcos. “Evaluation of Lactobacillus coryniformis CECT5711 strain as a coadjuvant in a vaccination process: A randomised clinical trial in healthy adults.” Nutrition & Metabolism, Vol. 14 (2017): 2.
  29. Kukkonen, K., T. Nieminen, T. Poussa, E. Savilahti, and M. Kuitunen. “Effect of probiotics on vaccine antibody responses in infancy—A randomized placebo-controlled double-blind trial.” Pediatric Allergy and Immunology, Vol. 17, No. 6 (2006): 416–421.
  30. de Vrese, M., P. Rautenberg, C. Laue, M. Koopmans, T. Herremans, and J. Schrezenmeir. “Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination.” European Journal of Nutrition, Vol. 44, No. 7 (2005): 406–413.
  31. Davidson, L.E., A.‑M. Fiorino, D.R. Snydman, and P.L. Hibberd. “Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: A randomized double-blind placebo-controlled trial.” European Journal of Clinical Nutrition, Vol. 65, No. 4 (2011): 501–507.
  32. Rizzardini, G., D. Eskesen, P.C. Calder, A. Capetti, L. Jespersen, and M. Clerici. “Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB‑12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: A randomised, double-blind, placebo-controlled study.” The British Journal of Nutrition, Vol. 107, No. 6 (2012): 876–884.
  33. Najafzadeh, H., M. Ghorbanpour, M. Mayahi, and H. Gavzan. “Effect of Echinacea purpurea on antibody production against fowl influenza vaccine.” Journal of Applied Animal Research, Vol. 39, No. 2 (2011): 139–141
  34. Talazadeh, F., M. Mayahi, and M. Naghavi. “The effect of Antibiofin® on the immune response against avian influenza subtype H9N2 vaccine in broiler chickens.” International Journal of Enteric Pathogens, Vol. 4, No. 3 (2016): e39396.
  35. Zhang, P., J. Wang, W. Wang, X. Liu, H. Liu, X. Li, and X. Wu. “Astragalus polysaccharides enhance the immune response to avian infectious bronchitis virus vaccination in chickens.” Microbial Pathogenesis, Vol. 111 (2017): 81–85.
  36. Sherman, M.P., C.J. Pritzl, C. Xia, M.M. Miller, H. Zaghouani, and B. Hahm. “Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice.” Biochemical and Biophysical Research Communications, Vol. 467, No. 4 (2015): 766–770.
  37. Zhu, H., M. Hu, D. Wang, G. Xu, X. Yin, X. Liu, M. Ding, and L. Han. “Mixed polysaccharides derived from shiitake mushroom, poriacocos, ginger, and tangerine peel enhanced protective immune responses in mice induced by inactivated influenza vaccine.” Biomedicine & Pharmacotherapy, Vol. 126 (2020): 110049.
  38. Girodon, F., P. Galan, A.L. Monget, M.C. Boutron‑Ruault, P. Brunet‑Lecomte, P. Preziosi, J. Arnaud, J.C. Manuguerra, and S. Herchberg. “Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: A randomized controlled trial. MIN. VIT. AOX. geriatric network.” Archives of Internal Medicine, Vol. 159, No. 7 (1999): 748–754.